What's new

[PIO] Questions - answers on the adapted, updated COVID-19 vaccines

30192.jpg





Why is it necessary to have a wide range of vaccines available against COVID-19?

As the COVID-19 pandemic continues, with new waves of infections expected during the winter season, there is a need for the availability of a wide range of COVID-19 vaccines that match different variants of the SARs-CoV-2 virus and that can be used safely to protect people from severe effects of COVID-19.

It is not known which adapted vaccines will offer the highest protection, as it cannot be predicted which variants of the virus will emerge and become available later in the autumn/winter.

Therefore, all licensed adapted vaccines will be valid options for future vaccination campaigns.

Why do vaccines need to be adapted (i.e. updated)?

Vaccines are adapted (i.e. updated) to better match the circulating variants of SARs-CoV-2 virus.

Adapted vaccines can broaden protection against different variants, thereby helping to maintain optimal protection against COVID-19 as the virus evolves.

It is expected that the recently approved custom vaccines will broaden immunity against variants of concern, particularly Omicron and its sub-variants.

How safe are custom vaccines?

Data from clinical trials with custom bivalent vaccines show that their safety profile is similar to the original monovalent vaccines.

The safety profile of all newly licensed custom vaccines is expected to be comparable to that of already licensed mRNA-technology monovalent vaccines, for which a large amount of data is available.

How will custom vaccines be used?

Custom vaccines are currently licensed for use as booster doses in persons aged 12 years and older who have completed at least the initial regimen/primary vaccination, regardless of which vaccines were used in that regimen.

The use of adapted vaccines should remain restricted as booster doses for the time being.

What happens to the original/primary vaccines against COVID-19?

Initial/prototype vaccines remain effective in preventing serious illness, hospitalisation and death associated with COVID-19, and it is therefore recommended that they continue to be used in vaccination campaigns in the European Union, particularly for initial (primary) vaccination schemes.

It is noted that in view of a possible autumn outbreak of COVID-19 cases, early vaccination, in line with the relevant national recommendations, is considered essential to protect public health and prevent overloading of the health system.

* The answers to the above questions are based on the scientific evidence available so far and the current recommendations of European public health organisations, which are continuously updated.

Πηγές www.ema.europa.eu, www.ecdc.europa.eu

(AF)
Contents of this article including associated images are owned by PIO
Views & opinions expressed are those of the author and/or PIO

Source

 
Back
Top